EA201991164A1 - APPLICATION OF PERTUZUMAB HER2 DIMERIZATION INHIBITOR AS AN INDUSTRIAL PRODUCT AND INDUSTRIAL PRODUCT INCLUDING PERTUZUMAB HER2 DIMERIZATION INHIBITOR - Google Patents
APPLICATION OF PERTUZUMAB HER2 DIMERIZATION INHIBITOR AS AN INDUSTRIAL PRODUCT AND INDUSTRIAL PRODUCT INCLUDING PERTUZUMAB HER2 DIMERIZATION INHIBITORInfo
- Publication number
- EA201991164A1 EA201991164A1 EA201991164A EA201991164A EA201991164A1 EA 201991164 A1 EA201991164 A1 EA 201991164A1 EA 201991164 A EA201991164 A EA 201991164A EA 201991164 A EA201991164 A EA 201991164A EA 201991164 A1 EA201991164 A1 EA 201991164A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- her2
- pertuzumab
- cancer
- treatment
- application
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Настоящая заявка описывает применение и промышленные изделия, включающие пертузумаб, наилучший в своем классе ингибитор димеризации HER2. В частности, заявка относится к способам для продления выживаемости без прогрессирования в популяции пациентов с HER2-положительным раком молочной железы; к сочетанию двух антител против HER2 для лечения HER2-положительного рака без повышения кардиотоксичности; к лечению ранней стадии HER2-положительного рака молочной железы; к лечению HER2-положительного рака путем совместного введения смеси пертузумаба и трастузумаба из одного пакета для внутривенного введения; к лечению HER2-положительного метастатического рака желудка; к лечению HER2-положительного рака молочной железы пертузумабом, трастузумабом и винорелбином; к лечению HER2-положительного рака молочной железы пертузумабом, трастузумабом и ингибитором ароматазы и к лечению рака яичника с низким уровнем HER3, первичной перитонеальной злокачественной опухоли или злокачественной опухоли фаллопиевых труб. Заявка также описывает промышленное изделие, включающее в себя флакон с пертузумабом внутри и вкладыш в упаковку, предоставляющий данные по безопасности и/или данные по эффективности; способ производства промышленного изделия и способ для обеспечения безопасного и эффективного применения пертузумаба, относящийся к изделию. Кроме того, заявка описывает пакет для внутривенного (в/в) введения, содержащий стабильную смесь пертузумаба и трастузумаба, подходящую для введения пациенту с раком.This application describes application and industrial products including pertuzumab, the best-in-class HER2 dimerization inhibitor. In particular, the application relates to methods for prolonging progression-free survival in a population of patients with HER2-positive breast cancer; a combination of two antibodies against HER2 for the treatment of HER2-positive cancer without increasing cardiotoxicity; treatment of an early stage of HER2-positive breast cancer; treating HER2-positive cancer by co-administering a mixture of pertuzumab and trastuzumab from a single intravenous packet; treatment of HER2-positive metastatic cancer of the stomach; treatment of HER2-positive breast cancer with pertuzumab, trastuzumab and vinorelbine; treatment of HER2-positive breast cancer with pertuzumab, trastuzumab and an aromatase inhibitor; and treatment of ovarian cancer with low HER3, a primary peritoneal cancer or a fallopian tube cancer. The application also describes an industrial product including a bottle with pertuzumab inside and a package insert providing safety data and / or efficacy data; a method of manufacturing an industrial product; and a method for providing safe and effective use of pertuzumab related to the product. In addition, the application describes a package for intravenous (iv) administration containing a stable mixture of pertuzumab and trastuzumab, suitable for administration to a patient with cancer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261694584P | 2012-08-29 | 2012-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201991164A1 true EA201991164A1 (en) | 2019-09-30 |
Family
ID=68000202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201991164A EA201991164A1 (en) | 2012-08-29 | 2012-10-11 | APPLICATION OF PERTUZUMAB HER2 DIMERIZATION INHIBITOR AS AN INDUSTRIAL PRODUCT AND INDUSTRIAL PRODUCT INCLUDING PERTUZUMAB HER2 DIMERIZATION INHIBITOR |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA201991164A1 (en) |
-
2012
- 2012-10-11 EA EA201991164A patent/EA201991164A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500519A1 (en) | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab | |
NZ719784A (en) | Specific anti-cd38 antibodies for treating human cancers | |
PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
EA201591371A1 (en) | Pyridine derivatives as easily degraded inhibitors ROCK | |
EA201591166A1 (en) | AUTOTAXIN INHIBITORS | |
MX2015014751A (en) | Compositions and methods for the treatment of immunodeficiency. | |
MX2015015110A (en) | Antibody specifically binding to her2. | |
MX2019013753A (en) | Anti-folr1 immunoconjugates and anti-pd-1 antibody combinations. | |
MX2018006953A (en) | Monomaleimide-functionalized platinum compounds for cancer therapy. | |
AU2018256669A1 (en) | Combination therapy | |
HRP20230523T1 (en) | Antitumor agent and antitumor effect enhancer | |
MX2017014396A (en) | Treatment for multiple myeloma (mm). | |
MX2017013358A (en) | Methods for treating cancer. | |
BR102012028120B8 (en) | USE OF ONE OR MORE INGENOL DERIVATIVES, PHARMACEUTICAL COMPOSITION AND DRUG | |
MX2016006894A (en) | Combination therapy comprising an inhibitor of jak, cdk and pim. | |
EA201400495A1 (en) | SELECTIVE INHIBITORS THROUGH THE INTERACTION OF THE RECEPTOR OF FIBROBLAST GROWTH FACTOR AND FRS2, FOR PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES | |
PH12016500677A1 (en) | Specific anti-cd38 antibodies for treating human cancers | |
EA201991164A1 (en) | APPLICATION OF PERTUZUMAB HER2 DIMERIZATION INHIBITOR AS AN INDUSTRIAL PRODUCT AND INDUSTRIAL PRODUCT INCLUDING PERTUZUMAB HER2 DIMERIZATION INHIBITOR | |
MX2016006927A (en) | Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis. | |
MX2015016893A (en) | Combination of ro5503781 and capecitabine for cancer therapy. | |
EA201791075A1 (en) | METHODS OF TUMOR TREATMENT USING CDIS × CD20 BISPECIFIC ANTIBODIES | |
UA105159C2 (en) | Method for treating recurrent varicose of lower limbs |